We are entering the genomics era

In a study of over 10,000 adults, ~16% of the study participants were found to have a high-impact or moderate-impact inherited mutation. Of those that tested positive, the majority had pre-disposing variants related to hereditary cancer syndromes or variants associated with cardiovascular disorders. We believe that proactive genetic health screening should be accessible and affordable for everyone that wants it.

In a cohort of 52,069 solid tumor samples 92% harbored at least one oncogenic mutation and 34% harbored at least one mutation classified as a predictive biomarker of response to an FDA-approved drug. We believe that comprehensive tumor profiling should be a part of routine care for cancer patients.

Of patients tested for 301 genes on an expanded carrier screening panel, 78% of patients were found to be carriers of a mutation for a recessive condition. We believe that families should have access to the appropriate genetic counseling and testing to understand their genetic risks and inform family planning.

In a study of over 10,000 patients that underwent preemptive, panel-based pharmacogenomic testing, 91% of the patients were identified to have one or more actionable variant. We believe that pharmacogenomics is heavily under-utilized and should be available to everyone to tailor their treatment to their unique genetic makeup.